key: cord-0786766-ea12kg56
authors: Pala, Laura; Conforti, Fabio; Saponara, Maristella; De Pas, Tommaso; Giugliano, Federica; Salè, Emanuela Omodeo; Jemos, Costantino; Marco, Rubatto; Andrea, Agostini; Quaglino, Pietro; Fava, Paolo; Fierro, Maria Teresa; Queirolo, Paola
title: Data of Italian Cancer Centers from two regions with high incidence of Sars CoV-2 infection provide evidence for the successful management of patients with locally advanced and metastatic melanoma treated with immunotherapy in the era of COVID-19
date: 2020-08-07
journal: Semin Oncol
DOI: 10.1053/j.seminoncol.2020.07.010
sha: 4905e5c3dc367c39fb25c15e4d5374f6d32ecc66
doc_id: 786766
cord_uid: ea12kg56

Background: Patients with cancer are presumed to have a higher risk to contract SARS-CoV-2 infection, because of their immunosuppressed status. The impact and course of COVID-19 infection in cancer patients receiving immunotherapy remains unknown. Objectives: To evaluate the safety of the management of patients with advanced melanoma treated with immunotherapy in two Cancer Centers located in areas of Italy with a high incidence of COVID-19 infections. Methods: We retrospectively analyzed data from January 1 to April 30, 2020 on patients with locally advanced and metastatic melanoma receiving immunotherapy at either Istituto Europeo di Oncologia (IEO) or Città della Salute e della Scienza University Hospital (CSSUH). Results: One-hundred and sixty nine patients with stage III and IV melanoma were treated with an immunotherapy regimen at either IEO or CSSUH. One-hundred and four patients continued treatment without interruption or delay, while 49 patients had a treatment delay. The main reasons for treatment delay were older age (median age of the group of patients with or without treatment-delay, respectively 60 and 69 years, p-value <0.001) and/or presence of comorbidities (percentage of patients with at least one comorbidity respectively 81% and 62%, in patients with or without treatment delay, p-value=0.001). One-hundred and twelve patients had at least one thoracic CT scan performed and radiological findings suspicious for COVID-19 were observed in only seven cases (4%). Fifteen patients (9%) developed symptoms potentially related to COVID-19; naso-pharingeal swabs were collected in nine patients and only one was positive for SARS-CoV-2. Conclusions The incidence of symptomatic COVID-19 infection observed in our cohort of patients with advanced malignant melanoma treated with immunotherapy appears meaningfully lower as compared with that reported in the overall population in Italy as well as in patients affected by solid tumors. We conclude that in patients with locally advanced and metastatic melanoma, immunotherapy can be safely continued without delay in the majority of cases, reserving precautionary delay only for the most frail patients.

Results: One-hundred and sixty nine patients with stage III and IV melanoma were treated with an immunotherapy regimen at either IEO or CSSUH. Onehundred and four patients continued treatment without interruption or delay, while 49 patients had a treatment delay. The main reasons for treatment delay were older age (median age of the group of patients with or without treatmentdelay, respectively 60 and 69 years, p-value <0.001 ) and/or presence of comorbidities (percentage of patients with at least one comorbidity respectively 81% and 62%, in patients with or without treatment delay, p-value=0.001).

One-hundred and twelve patients had at least one thoracic CT scan performed and radiological findings suspicious for COVID-19 were observed in only seven cases (4%). Fifteen patients (9%) developed symptoms potentially related to COVID-19; naso-pharingeal swabs were collected in nine patients and only one was positive for SARS-CoV-2.

The incidence of symptomatic COVID-19 infection observed in our cohort of patients with advanced malignant melanoma treated with immunotherapy appears meaningfully lower as compared with that reported in the overall population in Italy as well as in patients affected by solid tumors.

We conclude that in patients with locally advanced and metastatic melanoma, immunotherapy can be safely continued without delay in the majority of cases, reserving precautionary delay only for the most frail patients. The COVID-19 pandemic has emerged as a major worldwide health concern, with millions of people infected and hundreds of thousands dead. As of July 2020, Italy still ranks as one of the countries with the highest incidence of COVID-19 in the world. [1] The Lombardy and Piedmont regions account for over 50% of total cases and over 60% of deaths for COVID-19 infection in the country. [2] Because of their immunosuppressed status conferred by either the tumor itself or by anti-cancer treatments, including chemotherapy and radiotherapy, patients with cancer are generally thought to have a higher risk of developing infectious complications. [3] However, the impact and course of viral infection in cancer patients receiving immunotherapy remains largely unknown. Thus, we retrospectively collected and analyzed data on patients with a diagnosis of melanoma who were treated with immunotherapy from January 1 to April 30, 2020 at two Italian Cancer Centers, Istituto Europeo di Oncologia (IEO) and

Città della Salute e della Scienza University Hospital, located respectively in Milan (Lombardy) and Turin (Piedmont).

In total 169 patients with a diagnosis of either stage III or stage IV melanoma undergoing treatment with an immunotherapy containing regimen presented to the outpatient clinics of the IEO or the Città della Salute e della Scienza University Hospital. Table 1 The median length of treatment delay was 4 weeks, ranging from 3 to 9

weeks. In about half of cases, the reason leading to treatment delay was to avoid hospital admission of patients at higher risk for COVID-19, such as those who were older -the median age of the group of patients with or without treatmentdelay, was respectively 60 versus 69 years, p-value <0.001) and/or had comorbidities -the percentage of patients with at least one comorbidity was respectively 81% and 62%, in patients with or without treatment delay, p-value=0.001). All patients whose treatment administration was delayed, had been on therapy for at least four months before delay and their disease was felt to be under control.

All patients evaluated, had access to one of the two centers or were contacted by phone to assess their health status and query regarding the onset of new symptoms in the prior two weeks. During the study period, only 15 patients (9%) developed new-onset symptoms potentially related to COVID-19, including fever, cough, dyspnea, anosmia, disgeusia or diarrhea.

A total of 112 patients had at least one thoracic CT scan performed as follow up of their oncologic disease, and radiological findings suspicious for COVID-19 were observed only in seven cases (4%). Naso-pharingeal swabs were collected in nine patients with clinical and/or suspicious radiologic findings, and only one was positive for SARS-CoV2. The latter patient, a 55 years old male, without comorbidities, had been receiving pembrolizumab for 2 years and had achieved a complete response. He experienced a paucisymptomatic COVID-19 infection, with moderate fever and anosmia lasting 4 days, and a mild bilateral pulmonary interstitial involvement highlighted on radiologic scans. Therapy with hydroxychloroquine and azythromycin was administered, with swabs negative for SARS-CoV-2 after 1 month.

The incidence of symptomatic COVID-19 infection observed in our cohort of patients, appears meaningfully lower as compared with that reported in the overall population in Italy as well as in patients affected by solid tumors. Funding source: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. 

The Civil Protection Department of the Italian Governament

COVID-19 deaths in Lombardy, Italy: data in context

Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China

Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System

Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease